Hereditary Angioedema News and Research

RSS

FDA approves Berinert for treating HAE in adults and adolescents

Berinert®, a human C1 esterase inhibitor (C1-INH) for treating acute episodes of facial or abdominal hereditary angioedema (HAE) in adults and adolescents has obtained approval from the US Food and Drug Administration (FDA).

25 Nov 2009

New data on diagnosis and treatment of allergic diseases to be presented at the ACAAI meeting

Researchers are unveiling new data on investigational findings in nearly 450 abstracts on the diagnosis and treatment of allergic diseases at the ACAAI Annual Meeting in Miami Beach, Fla., Nov. 5-10.

9 Nov 2009

HAE patients have prodromal symptoms that signal an oncoming HAE attack, reports survey

Most patients with hereditary angioedema (HAE) have prodromal symptoms that signal an oncoming HAE attack giving the patients sufficient time to initiate treatment and decrease the morbidity associated with that attack, according to survey findings presented today at the 2009 American College of Allergy, Asthma & Immunology (ACAAI) Annual Meeting.

9 Nov 2009

Evaluation of DX-88 to resolve symptoms of acute HAE attacks to be presented

An analysis demonstrating the ability of DX-88 (ecallantide) to resolve symptoms of acute hereditary angioedema (HAE) attacks in all anatomic locations and to sustain effect will be presented in an oral presentation this week at the American College of Allergy, Asthma and Immunology (ACAAI) 2009 Annual Meeting in Miami Beach.

9 Nov 2009

Shire announces third quarter 2009 financial results

Shire plc, the global specialty biopharmaceutical company, announces results for the three months to September 30, 2009.

31 Oct 2009

Dyax reports financial results for third quarter 2009; attracts a net loss of $0.17 per share

Dyax Corp. today announced financial results for the third quarter ended September 30, 2009. Dyax will host a webcast and conference call at 10 a.m. (ET) this morning to review the financial results and corporate progress for the quarter.

28 Oct 2009

FDA approves Berinert for adults and adolescents with HAE

The U.S. Food and Drug Administration today approved Berinert, the first treatment for acute abdominal attacks and facial swelling associated with a rare and potentially life-threatening genetic disease called hereditary angioedema (HAE).

27 Oct 2009

Study reveals benefits of recombinant human C1 inhibitor in treating ischemic brain injury

Biotech company Pharming Group NV announced today publication of a preclinical study showing the benefit of using recombinant human C1 inhibitor (rhC1INH) in ischemic brain injury.

23 Oct 2009

FDA grants marketing approval for CSL Behring's Berinert C1-Esterase Inhibitor

CSL Behring announced today that the U.S. Food and Drug Administration (FDA) has granted marketing approval for Berinert® C1-Esterase Inhibitor, Human for the treatment of acute abdominal or facial attacks of hereditary angioedema (HAE), a rare and serious genetic disorder, in adult and adolescent patients. Berinert is the first and only therapy approved for this indication in the U.S.

12 Oct 2009

FDA approves Berinert for the treatment of hereditary angioedema

12 Oct 2009

Dyax' Phase 3 hereditary angioedema clinical program affirms reliability of its novel PROs

Dyax Corp. (NASDAQ:DYAX) today announced a study published evaluating the Company’s novel Patient Reported Outcome Measures (PROs) used to assess hereditary angioedema (HAE) attacks affirmed the PROs as valuable instruments in capturing HAE symptom severity and impact of treatment.

11 Sep 2009

New Marketing Authorization Application for Rhucin submitted to the EMEA by Pharming

Biotech company Pharming Group NV ("Pharming" or "the Company") (NYSE Euronext: PHARM) today announced that it has submitted the Marketing Authorization Application (MAA) for Rhucin for the treatment of acute attacks of Hereditary Angioedema (HAE) to the European Medicines Agency (EMEA).

3 Sep 2009

FDA grants priority review of Cinryze C1 inhibitor as treatment for acute attacks of hereditary angioedema

ViroPharma Incorporated has announced that the U.S. Food and Drug Administration (FDA) has granted priority review for Cinryze C1 Inhibitor (human) as a treatment for acute attacks of Hereditary Angioedema (HAE).

5 Feb 2009

ViroPharma Inc. submits sBLA for Cinryze to treat acute attacks of hereditary angioedema

ViroPharma Inc. has announced that the company submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) for Cinryze C1 Inhibitor (human) as a treatment for acute attacks of hereditary angioedema (HAE).

1 Dec 2008

FDA accepts filing and grants priority review for DX-88 for hereditary angioedema

Dyax Corp. has announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the Company's Biologics License Application (BLA) for DX-88 (ecallantide) for the treatment of acute attacks of hereditary angioedema (HAE) and has designated the application for Priority Review.

21 Nov 2008

FDA licenses for marketing Cinryze for hereditary angioedema

The U.S. Food and Drug Administration today licensed for marketing the first product in the United States intended to protect people with hereditary angioedema (HAE), a rare and potentially life-threatening genetic disease. HAE affects about 6,000 to 10,000 individuals in the United States.

12 Oct 2008

Highly promising Alzheimer's and Parkinson's research

The TI Pharma project is a large-scale study into the brain material of Alzheimer's and Parkinson's patients, who gave permission to the Netherlands Brain Bank for their tissue to be used for scientific research.

17 Dec 2007

Hope on the horizon for hereditary angioedema sufferers

Although there is currently no treatment approved by the Federal Drug Administration (FDA) for acute attacks of hereditary angioedema (HAE) - a genetic disease causing swelling of extremities, face and internal organs that can be life-threatening - hope is on the horizon according to a team of experts presenting the latest research at the Annual Meeting of the American College of Allergy, Asthma and Immunology (ACAAI) in Dallas.

14 Nov 2007

Hereditary Angioedema News and Research

FDA approves Berinert for treating HAE in adults and adolescents

New data on diagnosis and treatment of allergic diseases to be presented at the ACAAI meeting

HAE patients have prodromal symptoms that signal an oncoming HAE attack, reports survey

Evaluation of DX-88 to resolve symptoms of acute HAE attacks to be presented

Shire announces third quarter 2009 financial results

Dyax reports financial results for third quarter 2009; attracts a net loss of $0.17 per share

FDA approves Berinert for adults and adolescents with HAE

Study reveals benefits of recombinant human C1 inhibitor in treating ischemic brain injury

FDA grants marketing approval for CSL Behring's Berinert C1-Esterase Inhibitor

FDA approves Berinert for the treatment of hereditary angioedema

Dyax' Phase 3 hereditary angioedema clinical program affirms reliability of its novel PROs

New Marketing Authorization Application for Rhucin submitted to the EMEA by Pharming

FDA grants priority review of Cinryze C1 inhibitor as treatment for acute attacks of hereditary angioedema

ViroPharma Inc. submits sBLA for Cinryze to treat acute attacks of hereditary angioedema

FDA accepts filing and grants priority review for DX-88 for hereditary angioedema

FDA licenses for marketing Cinryze for hereditary angioedema

Highly promising Alzheimer's and Parkinson's research

Hope on the horizon for hereditary angioedema sufferers

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News